Rallybio Corp
RLYB
View Detailed Chart
8.260USD
+0.040+0.49%
Market hours （ET）Quotes delayed by 15 min
13.49MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.49%
5 Days
-6.88%
1 Month
+9.55%
6 Months
+1382.94%
Year to Date
+1103.91%
1 Year
+1190.42%
View Detailed Chart
TradingKey Stock Score of Rallybio Corp
Currency: USD Updated: 2026-03-27Key Insights
Rallybio Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 155 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 8.00.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Rallybio Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Rallybio Corp Highlights
StrengthsRisks
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Growing
The company is in a growing phase, with the latest annual income totaling USD 858.00K.
Undervalued
The company’s latest PE is -5.15, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.55M shares, decreasing 20.02% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 127.03K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.43.
Analyst Rating
Based on
2
analysts
Hold
Current Rating
8.000
Target Price
+6.10%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Rallybio Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Rallybio Corp Info
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Ticker SymbolRLYB
CompanyRallybio Corp
CEOUden (Stephen)
Websitehttps://rallybio.com/
Related Instruments
-0.68%
+1.29%
+0.69%
+3.01%
-0.68%
+0.72%
+1.24%
-0.89%
+0.49%
-0.63%
-2.62%
+0.01%
+0.70%
+0.59%
-3.01%
0.00%
+0.19%
-0.48%
+1.25%
-1.52%Popular Symbols
246.576
-6.314 (-2.50%)
167.700
+0.180 (+0.11%)
67635.420
+1051.370 (+1.58%)
258.695
-16.645 (-6.05%)
2067.500
+67.500 (+3.38%)
363.910
+2.080 (+0.57%)
4538.370
+45.850 (+1.02%)
101.692
+1.083 (+1.08%)
1.145
-0.005 (-0.47%)
159.585
-0.667 (-0.42%)
